Ajanta Pharma ties up with Biocon to sell generic semaglutide in overseas market
Ajanta Pharma plans to sell generic semaglutide in 26 countries, in a partnership with Biocon, capitalizing on patent expirations. With a strong foothold in emerging markets and a potential 10x market growth, Ajanta aims to become a leading player in the global GLP-1 market by 2027.
Ajanta Pharma plans to sell generic semaglutide in 26 countries, in a partnership with Biocon, capitalizing on patent expirations. With a strong foothold in emerging markets and a potential 10x market growth, Ajanta aims to become a leading player in the global GLP-1 market by 2027.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
